There is no single best treatment for prurigo nodularis (PN), but a clear treatment ladder exists: start with topical therapies for mild disease, then escalate to systemic medications when nodules are widespread or itch is uncontrolled. Since 2022, two biologic injections have been FDA-approved specifically for PN, marking a major shift for a condition that previously had no approved treatments at all.
The right approach depends on how many nodules you have, how severe the itch is, and whether an underlying trigger (like kidney disease, thyroid problems, or eczema) is driving the condition. Most people need a combination of strategies targeting both the skin and the itch signals in the nervous system.
Topical Treatments for Mild PN
If you have a limited number of nodules, high-potency topical corticosteroids are the standard starting point. These work by suppressing the immune cells and inflammatory signals that fuel both the nodules and the itch. Clinical guidelines recommend them as the go-to for mild PN, and they’re often applied under an occlusive dressing to boost absorption into the thickened skin. Hydrocolloid bandages work particularly well for this because they stick to the skin reliably and also create a physical barrier that protects the nodule from scratching.
For nodules that don’t respond to topical steroids alone, corticosteroid injections directly into the lesion can flatten them effectively. This approach is generally recommended when you have fewer than 20 nodules. It delivers a concentrated dose right where it’s needed and can provide relief that lasts weeks to months per injection.
Topical calcineurin inhibitors offer an alternative for people who need long-term maintenance therapy or can’t tolerate steroids. These are especially useful on thinner skin areas where prolonged steroid use carries a higher risk of skin thinning. They suppress the local immune response through a different pathway than steroids, making them a practical option for ongoing care.
Biologics: The Biggest Advance in PN Treatment
For PN that can’t be controlled with topical treatments, biologic injections have become the recommended first-line systemic therapy. This is a relatively new development. Before 2022, there were zero FDA-approved medications for prurigo nodularis.
Dupilumab was the first to receive FDA approval in September 2022 for adults with PN. It works by blocking a receptor involved in the type of immune overactivation that drives both itch and nodule formation. Clinical guidelines now position it as the preferred first systemic step when topical therapies fail, giving it the highest level of evidence support among systemic options.
Nemolizumab, approved more recently, targets a different itch-driving pathway by blocking the receptor for interleukin-31, a signaling molecule heavily involved in the nerve-to-skin itch cycle that characterizes PN. In a phase 3 trial published in the New England Journal of Medicine, 56.3% of patients on nemolizumab achieved a meaningful reduction in itch intensity at 16 weeks, compared to 20.9% on placebo. Both biologics are given as injections, typically self-administered at home every few weeks.
Systemic Immunosuppressants
Before biologics became available, immunosuppressants like methotrexate and cyclosporine were the main systemic options, and they still play a role when biologics aren’t accessible or aren’t working. Methotrexate is typically given as a weekly dose, often starting around 10 to 15 mg, and improvements in nodule thickness and itch can take 7 weeks or longer to appear. Folic acid supplementation is standard alongside it to reduce side effects like nausea and mouth sores.
These medications require regular blood work to monitor for effects on the liver, kidneys, and blood cell counts. They’re generally considered second-line now that biologics with better safety profiles are available. One important note from clinical guidelines: long-term systemic corticosteroids (like prednisone pills) are not recommended for PN. The rebound flares when you taper off tend to make the condition worse, and the long-term side effects aren’t justified for a chronic condition.
Targeting the Nerve Component of Itch
PN isn’t purely a skin disease. The itch has a strong neurological component, with nerve fibers in the skin becoming hypersensitized over time. This is why the itch can feel so disproportionately intense and why it often peaks at night, disrupting sleep.
Gabapentin, originally developed for seizures, has become a widely used tool for this nerve-driven itch. The dosing strategy for PN differs from how the drug is used for pain. Since the primary goal is controlling nighttime itch to allow sleep, treatment typically starts with a low dose of 100 mg taken at bedtime. From there, it can be gradually increased to 300 mg over a few weeks. If itch remains severe, a second evening dose is added earlier in the evening, creating a two-dose schedule (for example, 300 mg at 5 p.m. and 300 mg at 8 p.m.). For people with severe daytime itch as well, the dosing can be spread across three times daily, with a maximum of 3,600 mg per day. Pregabalin is an alternative that starts at 75 mg and follows a similar titration approach.
Drowsiness is the most common side effect, which actually works in your favor when the drug is dosed at night. The key is starting low and increasing slowly to find the dose that controls itch without causing excessive daytime grogginess.
Breaking the Itch-Scratch Cycle
One of the defining challenges of PN is the self-reinforcing loop: nodules itch, scratching thickens the skin, thickened skin itches more, and the cycle continues. Even with effective medications, addressing the behavioral side of this loop makes a meaningful difference.
Habit reversal training is a behavioral technique originally developed in the 1970s for nervous tics and repetitive habits. The core idea is straightforward: you learn to recognize the urge to scratch and replace it with a competing response, like clenching your fist or pressing a cool cloth against the skin. It doesn’t eliminate the itch, but it can significantly reduce the mechanical damage from scratching that keeps nodules from healing.
Physical barriers also help. Covering active nodules with hydrocolloid dressings serves double duty: the occlusion improves absorption of any topical medication underneath, and the bandage itself prevents direct scratching. Keeping nails short and wearing light gloves at night are simple additions that reduce the damage from unconscious scratching during sleep.
What a Typical Treatment Plan Looks Like
In practice, most dermatologists combine multiple approaches simultaneously rather than trying one thing at a time. A realistic treatment plan for moderate-to-severe PN might include a biologic injection as the systemic backbone, a high-potency topical steroid for the most bothersome nodules, gabapentin at night for sleep-disrupting itch, and hydrocolloid dressings on accessible lesions.
Improvement is gradual. Itch intensity often starts decreasing within the first few weeks of biologic therapy, but nodules themselves can take months to flatten. Older, well-established nodules are the slowest to resolve. Many people see the best results after three to six months of consistent combined treatment, and some form of maintenance therapy is usually needed long-term since PN tends to recur when treatment stops entirely.
If an underlying condition is contributing, such as chronic kidney disease, liver disease, or untreated eczema, managing that condition is an essential piece of the puzzle. PN that develops secondary to another disease is harder to control without addressing the root cause.